The Use of Biomarkers in the Risk Stratification of Cystic Neoplasms

Gastrointestinal Endoscopy Clinics of North America
Jeremy H Kaplan, Tamas A Gonda

Abstract

Cyst fluid biomarkers may be used to identify pancreatic cyst subtypes. Biomarkers are selected based on their ability to accurately distinguish mucinous from nonmucinous cysts and to risk stratify cysts based on malignant potential. Biomarkers of interest include but are not limited to amylase, oncogenes, DNA analysis, and epigenetic markers. The introduction of next-generation sequencing and molecular panels has aided in improved diagnostic accuracy and risk stratification. This review presents the diagnostic performance of currently available biomarkers and proposes an algorithm to incorporate their use in the diagnosis of pancreatic cysts.

Citations

Jul 3, 2020·Endoscopic Ultrasound·Vasile Daniel BalabanAdrian Saftoiu
Feb 14, 2020·International Journal of Molecular Sciences·Scarlett HaoAlexander A Parikh
Apr 17, 2020·Endoscopic Ultrasound·Chieh Sian Koo, Khek Yu Ho
Jan 6, 2021·Journal of Personalized Medicine·Sonia Hermoso-DuránOlga Abian
Jan 26, 2021·Clinical Endoscopy·Ahmad Najdat Bazarbashi, Linda S Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.